Avaleht500124 • BOM
add
Dr Reddy's Laboratories Ltd
Viimane sulgemishind
1194,55 ₹
Tänane vahemik
1194,00 ₹ - 1222,85 ₹
Aasta vahemik
1074,35 ₹ - 1420,20 ₹
Turuväärtus
1,01 trln INR
Keskmine maht
59,31 tuh
P/E suhe
18,98
Dividendimäär
0,66%
Põhibörs
NSE
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(INR) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 80,16 mld | 16,51% |
Põhitegevusega seonduv kulu | 29,72 mld | 24,54% |
Puhastulu | 12,55 mld | −15,18% |
Puhaskasumimarginaal | 15,66 | −27,20% |
Puhaskasum aktsia kohta | 15,83 | −11,13% |
EBITDA | 22,02 mld | 8,53% |
Tõhus maksumäär | 30,01% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(INR) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 63,07 mld | −7,15% |
Kogu vara | 465,96 mld | 34,27% |
Kõik kohustused | 156,67 mld | 66,79% |
Kogu omakapital | 309,28 mld | — |
Emiteeritud aktsiate arv | 833,05 mln | — |
Hinna ja väärtuse suhe P/B | 3,26 | — |
Varade tasuvus | 10,24% | — |
Kapitali tasuvus | 13,21% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(INR) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | 12,55 mld | −15,18% |
Põhitegevuse rahakäive | 9,32 mld | −48,03% |
Investeeringute raha | −19,07 mld | −322,21% |
Finantseerimise raha | 16,15 mld | 329,53% |
Raha ja raha ekvivalentide muutus | 6,37 mld | 1,03% |
Tasuta rahavoog | 3,92 mld | −72,47% |
Teave
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Tegevjuht
Asutatud
1984
Peakontor
Veebisait
Töötajate arv
27 048